Navigation Links
Arthritis Foundation Announces Amgen and Wyeth to Be Presenting Sponsor of the 2008 Arthritis Walk (R)
Date:12/11/2007

ATLANTA, Dec. 11 /PRNewswire-USNewswire/ -- The Arthritis Foundation, the leading health organization addressing the needs of 46 million Americans living with arthritis, today announced that Amgen and Wyeth Pharmaceuticals, co-marketers of Enbrel (R) (etanercept), will be the national presenting sponsor of the 2008 Arthritis Walk (R).

"The Arthritis Foundation hosts hundreds of Arthritis Walk events nationwide to raise funds to prevent, control and cure arthritis, the nation's most common cause of disability," said Becky Burkett, chief development officer of the Arthritis Foundation. "This generous sponsorship from Amgen and Wyeth will provide a unique opportunity to generate awareness about arthritis while raising funds that are critical to helping find a cure for this debilitating condition."

As part of the sponsorship, the Arthritis Foundation will launch a new program in which the organization will reach out to rheumatologists and members of the Association of Rheumatology Health Professionals in an effort to help boost attendance and awareness of the Arthritis Walk by encouraging doctors and their patients to walk together.

"We're excited to have the opportunity to support a program that benefits the entire arthritis community," said Jeffrey M. Melin, M.D., M.P.H., senior director, Musculoskeletal and Inflammatory Diseases, Wyeth Research. "We encourage people with arthritis to join the Arthritis Walk together with their doctor, as well as their friends and family, and to take an active role in improving their own health, while raising awareness and funding for arthritis research."

"Arthritis can pose challenges to physical activity, but it does not have to mean the end of an active and healthy lifestyle," said Scott Baumgartner, M.D., director, Global Development, Inflammation Therapeutic Area, Amgen. "We hope that together with the Arthritis Foundation we can empower and motivate people with rheumatoid arthritis to c
'/>"/>

SOURCE Arthritis Foundation
Copyright©2007 PR Newswire.
All rights reserved

Page: 1 2 3 4

Related medicine technology :

1. ORENCIA(R) (abatacept) Supplemental Biologics License Application for Juvenile Idiopathic Arthritis Accepted by FDA for Filing and Review
2. New Risk Gene for Rheumatoid Arthritis and Lupus Opens Door to More Effective Treatments
3. Trubion Announces Preliminary Analysis of Phase IIb Results With TRU-015 in Rheumatoid Arthritis
4. Targeted Genetics Reports on Recombinant DNA Advisory Committee (RAC) Review of its Phase 1/2 Trial of tgAAC94 for Rheumatoid Arthritis
5. Evidence of Benefit Lacking for Many Common Ways of Treating Osteoarthritis of the Knee
6. Cost-Effectiveness Study Supports Use of EUFLEXXA(TM) by Rheumatologists for Pain Relief in Patients with Knee Osteoarthritis
7. CIMZIA(R) (certolizumab pegol), Significantly Reduces Structural Damage and Rheumatoid Arthritis Signs & Symptoms for Up to One Year
8. Phase 3 Data Show New Anti-TNF, Golimumab, Significantly Improved Arthritis, Skin and Nail Manifestations in Patients with Psoriatic Arthritis
9. Two Pivotal Phase III Studies for Roches ACTEMRA(TM) (tocilizumab) Demonstrate Significant Improvement in Rheumatoid Arthritis Symptoms
10. Trubion Pharmaceuticals Announces Presentation of Positive Data From Phase IIb and Re-treatment Studies With TRU-015 in Patients With Rheumatoid Arthritis
11. Five-Year Data Demonstrate Long-Term Efficacy and Safety with ORENCIA(R) (abatacept) in Adults with Rheumatoid Arthritis Who had an Inadequate Response to Methotrexate
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:9/2/2014)... DALLAS , September 2, 2014 ... Chromatography Column Market by Type (Empty, Pre-packed, Analytical, Preparative), by Material ... Flash Chromatography, UFLC), TLC,SFC] - Forecast to 2018", published by ... Million in 2013. It is poised to grow at ... Million by 2018. Browse 90 market ...
(Date:9/2/2014)... 2014 Particle Sciences, the leading CDMO for ... development and manufacturing capabilities with the addition of a ... Particle Sciences, Associate Director Clinical Production, "The company has ... square footage, equipment and staff across the board, all ... has over 6000ft 2 of operating cleanroom and ...
(Date:9/2/2014)... , Sept. 2, 2014 /PRNewswire-iReach/ -- Ortho Development® ... Alpine™ Hip Stem, the latest addition to its ... Stem is intended for use in total hip ... http://photos.prnewswire.com/prnh/20140830/141676 Alpine was ... stem philosophy. ODEV,s engineers worked closely with a ...
Breaking Medicine Technology:Chiral Chromatography Column Market Worth $87.8 Million by 2018 2Chiral Chromatography Column Market Worth $87.8 Million by 2018 3Chiral Chromatography Column Market Worth $87.8 Million by 2018 4Particle Sciences Expands Drug Eluting Device Capabilities and Overall Clinical Trial Manufacturing Resources 2Ortho Development Receives FDA Clearance for Alpine Hip Stem 2
... 15 VION,PHARMACEUTICALS, INC. (Nasdaq: VION ) today ... to the pivotal Phase II trial of its lead ... novo poor-risk acute myelogenous leukemia (AML). Alan Kessman, ... reached this milestone in the pivotal Phase II trial ...
... Study to Explore the Efficacy of Novel Proteasome Inhibitor ... Patients with Relapsed and Refractory Multiple Myeloma, SOUTH ... Multiple Myeloma Research Consortium (MMRC) and Proteolix, Inc. today,announced ... Phase 2,clinical trial to study Proteolix,s potent and selective ...
Cached Medicine Technology:Vion Pharmaceuticals Completes Accrual of 85 Patients to its Pivotal Phase II Trial of Cloretazine(R) (VNP40101M) in Elderly AML 2Vion Pharmaceuticals Completes Accrual of 85 Patients to its Pivotal Phase II Trial of Cloretazine(R) (VNP40101M) in Elderly AML 3Vion Pharmaceuticals Completes Accrual of 85 Patients to its Pivotal Phase II Trial of Cloretazine(R) (VNP40101M) in Elderly AML 4The Multiple Myeloma Research Consortium (MMRC) and Proteolix Initiate Phase 2 Clinical Trial Investigating Carfilzomib for the Treatment of Multiple Myeloma 2The Multiple Myeloma Research Consortium (MMRC) and Proteolix Initiate Phase 2 Clinical Trial Investigating Carfilzomib for the Treatment of Multiple Myeloma 3The Multiple Myeloma Research Consortium (MMRC) and Proteolix Initiate Phase 2 Clinical Trial Investigating Carfilzomib for the Treatment of Multiple Myeloma 4
(Date:9/2/2014)... 2014 Today, Therapy Changes ... for Me?” The guide outlines common questions an individual ... addition to common types of groups an individual can ... from the interventions of the therapist, but also from ... group members,” says Rochelle Perper, Ph.D. and founder of ...
(Date:9/2/2014)... 02, 2014 The exciting information sessions ... professionals Carey Lewis and Bob Wiley. The ... those who have the desire to illuminate entertainment with ... performers could be invited to join the Bridge ... NC – Saturday, Sept. 6, Charlotte Convention Center, 501 ...
(Date:9/2/2014)... Las Vegas, NV (PRWEB) September 02, 2014 ... a leading provider of “Cloud Based” Medical Practice Business ... and a provider of Digital Cyber Security solutions for ... was recently interviewed on the trading floor of the ... Flynn. Mr. DeLaGarza stated that we are very ...
(Date:9/2/2014)... 02, 2014 On August 30, 2014, ... titled “Why You Should Wash Your Face .” ... the global population breathes air considered polluted by the ... lodge in the skin’s pores destroying its natural oils. ... free radicals that may cause cell damage, redness, ...
(Date:9/2/2014)... in California, the percentage undergoing a double mastectomy increased ... not associated with a lower risk of death than ... the September 3 issue of JAMA . The ... one breast was associated with a higher risk of ... , Randomized trials have demonstrated similar survival for patients ...
Breaking Medicine News(10 mins):Health News:Actors, Models and Talent for Christ Auditions Are Set for Charlotte and Omaha on Saturday, September 6, 2014 2Health News:Cloud Medical Doctor Software Corporation's CEO Interviewed by the Price Futures Group 2Health News:Cloud Medical Doctor Software Corporation's CEO Interviewed by the Price Futures Group 3Health News:Simon Ourian, Kim Kardashian’s Doctor: Air Pollution May Be Aging Your Skin 2Health News:Increase seen in use of double mastectomy 2Health News:Increase seen in use of double mastectomy 3
... written about health care disparities between Latinos and non-Latino whites, ... same disparities from the perspective of the patient, in terms ... But how do the physicians feel about ... face in treating Latino patients, compared with physicians whose patients ...
... by helicopter, an expensive choice that may not impact patient ... and time is of the essence, helicopter transport is generally ... ground ambulance, but a paper published today in the online ... that the actual times to treatment for patients transported by ...
... HealthDay Reporter , WEDNESDAY, Oct. 12 (HealthDay ... for patients with a condition known as Barrett,s esophagus ... a large new Danish study suggests. Analyzing records ... determined that those with Barrett,s esophagus -- a disorder ...
... By Amanda Gardner HealthDay Reporter , WEDNESDAY, Oct. 12 ... marijuana run more than twice the risk of crashing compared to ... if the driver has also been drinking alcohol. The ... Reviews believe the findings are especially relevant in light of ...
... , WEDNESDAY, Oct. 12 (HealthDay News) -- Black ... colon cancer have worse overall and recurrence-free survival rates than ... from nearly 15,000 black and white colorectal cancer surgery patients ... America between 1977 and 2002. All the patients received the ...
... WEDNESDAY, Oct. 12 (HealthDay News) -- The death toll from ... risen to 23, and a total of 116 people have ... Control and Prevention reported late Wednesday. The agency said ... 14, more cases might still emerge since Listeria monocytogenes ...
Cached Medicine News:Health News:Physicians treating Latinos have high hurdles to jump, study shows 2Health News:Interfacility helicopter ambulance transport of neurosurgical patients 2Health News:Esophageal Cancer Risk Less Dire for Certain Patients: Study 2Health News:Esophageal Cancer Risk Less Dire for Certain Patients: Study 3Health News:Pot Smoking May More Than Double Crash Risk 2Health News:Pot Smoking May More Than Double Crash Risk 3Health News:Blacks Fare Worse Than Whites After Colon Cancer Surgery 2Health News:Death Toll From Cantaloupe-Linked Listeria Outbreak Now Stands at 23 2
... Lyra-i system combines the longest available wavelength ... maximize patient safety and efficacy. The unique ... the therapeutic range to all targeted structures. ... ensuring patient safety. All Lyra-I patients are ...
... The Company's Aura-i Laser System is ... designed for office-based procedures. Its unique, integrated ... benign vascular, including telangiectasia on the leg ... leg veins. It can also be used ...
Surgisis Inguinal Hernia Matrix is implanted to reinforce soft tissues in the inguinal floor to repair inguinal hernias. Supplied sterile in peel-open packages. Intended for one-time use....
Used for implantation to reinforce soft tissue in the repair of a hernia or body wall defect. Supplied sterile in peel-open packages. Intended for one-time use....
Medicine Products: